2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Immunology, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3636 Outcomes of R-CEOP or R-GCVP in anthracycline-ineligible large B-cell lymphoma: A combined analysis from two large u.S. centers

Yumeng Zhang, MD, Madiha Iqbal, MBBS, MD2, Supreet Kaur, MD3, Tristan L'Esperance, MD4, Allison C Rosenthal, DO5, Arushi Khurana, MBBS6, Bijal Shah, MD, MS7, Lubomir Sokol, MD, PhD8, Celeste Bello, MD9, Leidy Isenalumhe, MD, MS10, Sameh Gaballa, MD11, Javier Pinilla-Ibarz, MD PhD12, Julio Chavez, MD13
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Mayo Clinic, Jacksonville, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 University of Wisconsin–Madison, Madison, Wisconsin, United States
5 Mayo Clinic, Phoenix, Arizona, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Mayo Clinic, Jacksonville, Florida, United States

Background: Anthracycline (AC)-based therapy is the cornerstone of frontline treatment for large B-cell lymphoma (LBCL), but factors such as prior AC exposure, significant cardiac disease, or frailty-related comorbidity may preclude its use. In these situations, AC-sparing alternatives such as etoposide- (R-CEOP) or gemcitabine-based (R-GCVP) regimens are commonly used, but data regarding their outcomes remain poorly understood, particularly in U.S. populations. We analyzed cohorts from two large U.S. centers (Mayo Clinic and Moffitt Cancer Center) to characterize efficacy, treatment delivery, and prognostic factors.

Methods: We retrospectively identified 85 patients with LBCL deemed ineligible for AC-based therapy and treated first-line with R-CEOP (n=69) or R-GCVP (n=16). Ineligibility was classified as prior AC exposure for an antecedent malignancy, cardiac disease, or other comorbidities. Endpoints were overall and complete response rates (ORR, CRR), overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS). Response was assessed both among evaluable patients and by intention-to-treat (ITT). Prognostic factors were tested by multivariable Cox regression (International Prognostic Index [IPI], age-adjusted Charlson Comorbidity Index [CCI], disease origin); competing-risks mortality was estimated by cumulative incidence.

Results: Median age was 72 years (range 48-89), with 15 patients (18%) older than 80; 68% had advanced-stage disease and 59% IPI 3-5. The cohort carried a high comorbidity burden: median CCI was 7 (IQR 5-9), 66% had reduced ejection fraction, 56% had clinically significant heart failure or cardiomyopathy, 41% had coronary artery disease, and 21% had prior AC exposure. Patients received a median of 6 cycles (range 1-6); 2 remained on treatment at data cutoff, and 60 of the remaining 83 (72%) completed planned therapy. Treatment discontinuation was most often disease-driven: of the 23 who did not complete planned therapy, 17 stopped for progression or death and only 5 for toxicity, with the reason unknown in 1. Toxicity prompted treatment interruption in 8 patients (9%) and discontinuation in 5 (6%). The responsible toxicities were predominantly infectious and hematologic: infection (6 interruptions, 4 discontinuations), cytopenia (5 and 2), and cardiac events (3 and 2); none were attributed to neuropathy. With median follow-up of 62.4 months, ORR and CRR were 77.9% and 66.2% among evaluable patients (70.6% and 60.0% by ITT). Median OS was 45.5 months, PFS 20.0 months, and DSS 103.4 months; 5-year OS, PFS, and DSS were 40.7%, 32.3%, and 65.5%. Outcomes did not differ by reason for ineligibility. On multivariable analysis, two factors independently predicted worse OS: high IPI (3-5) was the strongest determinant (OS adjusted HR 2.39, 95% CI 1.25-4.57, p=0.009; PFS HR 2.02, p=0.022), and higher CCI score was also independent (OS HR 1.23 per point, 1.07-1.41, p=0.004; PFS HR 1.16, p=0.03). Cell of origin was not prognostic. Non-lymphoma deaths accounted for a substantial share of mortality (5-year non-relapse mortality 21.9% vs lymphoma-related 32.9%), consistent with the long DSS. Cardiovascular events were the leading cause of non-relapse death (7 of 16), followed by second malignancy (3) and respiratory or infectious causes (3). No significant OS or PFS difference was observed between R-CEOP and R-GCVP, but this comparison was limited by small R-GCVP numbers and confounding by treating center.

Conclusions: In this two-center U.S. analysis of anthracycline-ineligible LBCL, R-CEOP and R-GCVP demonstrated encouraging response rates and durable survival outcomes despite a significant comorbidity burden and high-risk population, and represent excellent alternatives when patient factors or history preclude the use of standard AC-based regimens. Both lymphoma-intrinsic risk (IPI) and host comorbidity burden (CCI) independently predicted survival in this cohort. Integration of novel agents and/or immunotherapy approaches may help close the gap in this high-risk patient population.

Yumeng Zhang, MD: Curio Science - Honoraria; Plexus Communications - Honoraria; Acrotech Biopharma - Consultancy (Includes expert testimony); Citius Oncology - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Arima Genomics - Consultancy (Includes expert testimony); Kyowa Hakko Kirin Pharma, Inc. - Consultancy (Includes expert testimony); AbbVie, Inc. - Consultancy (Includes expert testimony)